Clinical Trials · NCT07446439
A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use
- Phase
- Phase 3
- Recruitment status
- Recruiting
- Sponsor
- Vanda Pharmaceuticals
- Enrollment
- 280
- Start date
- Mar 2026
- Locations
- 10 sites, United States
- Primary endpoint
- Proportion of participants with at least 1 vomiting episode per week in the tradipitant group compared to the placebo group as measured by a daily symptom diary.